Member Info for DaddyAIM

mate there is seasonality in such biz thus looking at sequential growht is wrong imo.
4Q22 vs 1Q23 was -3%.
1Q22 vs 1Q23 was 12.6% organic.

Q4 is usually a strong moonth for advertiser (xmas) thus the comparison is inacurate.

the issue with TRMR is the management. take them all out.

I estimate Q1 organic growth to be 12.6%. Yes a slowdown but consensus only forecast high single digit CAGR over the next 5yr. So the pull back is just wrong.

Monty - reported profitability for the year end has been confirmed in this morning AGM call.

gg- your post should be pined on every chat room of this website ahaha

Anyway CNIC is a huge buy.

Take a note

Regarding gross profit and gross profit margin. CNIC works with several media buyers, publishers, and advertisers like Google, resulting in significant pass-through-costs therefore it's more accurate to look at EBITDA / Gross Profit rather than just Gross Profit Margin (Gross profile / Revenue). For FY23 I forecast 48.2% (FY22: 48.4%) this compares to a peer group median of 43% and average of 44%. Thus CNIC is better.

Regarding the NED selling - keep cool - nothing to read here.

• He still holds 15.5m shares or > 5% of the company!
• His holding are back from an original investment in 2003, pre-IPO, so an he has a proven tracl record of backing CNIC and can’t be blamed for some occasional trimming here and there. He also sold a chunk in 2021 and few small sales in 2020 but that's all.

CNIC remains a cash generative machine - FCF is what matters.
My base is for FCF 5yr CAGR to be 10%.
At less than 8x fwd EPS - it's a steal.
The OM model is vertically integrated which gives it flexibility.
CEO expects a 20%+ CAGR for OM revenue over the next 5yr.
BUY!

Exactly

cruncing numbers will show that without the impairment - CNIC would have break even. Next year CNIC will be profitable on a reported basis.
Talking with executive, OP medium term CAGR is "high single digit" and OM is 20% !
The gross profile and cash generation of this company is incredible. Yes, margin are not sector leading, but what matters is the FCF generation and it's huge. On my numbers CNIC trades on a 9% FCF yield with a 3yr forward FCCF CAGR 10%.
CNIC IS WAY TOO CHEAP.

Strong growth across the board, some margin erosion but this is the trade off for growth.
Organic metrics grow double digit, margins remain super healthy, even on a reported basis with Net Income margin coming at 18%! Cash conversion reduced a bit to 79% but still remains very strong imo.
Outlook is strong, FY 22 momentum “has accelerated during Q1 2023”, with three record revenue months, absolute revenue growth of 52% and underlying organic revenue growth of 19%, a “Strong pipeline for the remainder of FY 23”. Management note they are upgrading FY23 expectations to £85m-£90m revenue (FactSet consensus yesterday was £86m) at an Adjusted EBITDA margin of 28-30%.
Valuation: undemanding with 15x fwd P/E, EV/EBITDA 9x ; uwarranted discount to peer group, it's a bout time this stock rerate... STRONG BUY

yep - same here - always thought that if the business momentum was not improving past 2023 I'd give up. Upward and onward now

about to explode higher

profitable and positive cash flow - fantastic -

Not a fan… too much adjustments

looking at trade size - this is very much retail flow... institutional remain sticky. The business model is very defensive, special in the current macro environment. Drug testing does not rely on CapEx spending.

OK.

This screams as oversold, RSI, MACD, Stochastic.
50% Fibo is 13.8p
Sell off is non-sense - adding more here

and sold chunky lots... panic selling

19% discount - TURBO BUY